SCI Pharmtech, Inc. (4119.TW)
TWD 69.1
(1.32%)
TWD 69.1
(1.32%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 6.69 Billion TWD | 34.88% |
| 2022 | 4.96 Billion TWD | 18.39% |
| 2021 | 4.18 Billion TWD | -8.32% |
| 2020 | 4.56 Billion TWD | 11.97% |
| 2019 | 4.08 Billion TWD | 7.72% |
| 2018 | 3.78 Billion TWD | 14.97% |
| 2017 | 3.29 Billion TWD | -7.17% |
| 2016 | 3.55 Billion TWD | 2.7% |
| 2015 | 3.45 Billion TWD | 7.33% |
| 2014 | 3.22 Billion TWD | 5.51% |
| 2013 | 3.05 Billion TWD | 92.83% |
| 2012 | 1.58 Billion TWD | 4.39% |
| 2011 | 1.51 Billion TWD | 0.79% |
| 2010 | 1.5 Billion TWD | 20.16% |
| 2009 | 1.25 Billion TWD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 6.69 Billion TWD | 0.12% |
| 2024 Q2 | 6.83 Billion TWD | 1.99% |
| 2023 Q4 | 6.69 Billion TWD | 20.43% |
| 2023 Q2 | 5.41 Billion TWD | 3.82% |
| 2023 Q3 | 5.55 Billion TWD | 2.58% |
| 2023 FY | 6.69 Billion TWD | 34.88% |
| 2023 Q1 | 5.21 Billion TWD | 5.16% |
| 2022 Q4 | 4.96 Billion TWD | 7.41% |
| 2022 Q3 | 4.61 Billion TWD | 1.12% |
| 2022 FY | 4.96 Billion TWD | 18.39% |
| 2022 Q2 | 4.56 Billion TWD | 3.8% |
| 2022 Q1 | 4.39 Billion TWD | 5.01% |
| 2021 Q2 | 4.25 Billion TWD | -4.59% |
| 2021 Q4 | 4.18 Billion TWD | -1.65% |
| 2021 FY | 4.18 Billion TWD | -8.32% |
| 2021 Q1 | 4.45 Billion TWD | -2.44% |
| 2021 Q3 | 4.26 Billion TWD | 0.15% |
| 2020 FY | 4.56 Billion TWD | 11.97% |
| 2020 Q3 | 4.24 Billion TWD | -8.41% |
| 2020 Q4 | 4.56 Billion TWD | 7.56% |
| 2020 Q1 | 4.31 Billion TWD | 5.61% |
| 2020 Q2 | 4.63 Billion TWD | 7.62% |
| 2019 Q1 | 3.97 Billion TWD | 4.86% |
| 2019 FY | 4.08 Billion TWD | 7.72% |
| 2019 Q4 | 4.08 Billion TWD | 3.24% |
| 2019 Q3 | 3.95 Billion TWD | -4.47% |
| 2019 Q2 | 4.13 Billion TWD | 4.16% |
| 2018 Q2 | 3.63 Billion TWD | 7.35% |
| 2018 Q4 | 3.78 Billion TWD | 2.46% |
| 2018 FY | 3.78 Billion TWD | 14.97% |
| 2018 Q1 | 3.38 Billion TWD | 2.84% |
| 2018 Q3 | 3.69 Billion TWD | 1.64% |
| 2017 Q3 | 3.25 Billion TWD | -9.25% |
| 2017 FY | 3.29 Billion TWD | -7.17% |
| 2017 Q4 | 3.29 Billion TWD | 1.19% |
| 2017 Q2 | 3.58 Billion TWD | 1.59% |
| 2017 Q1 | 3.53 Billion TWD | -0.49% |
| 2016 Q3 | 3.43 Billion TWD | -7.96% |
| 2016 Q4 | 3.55 Billion TWD | 3.24% |
| 2016 FY | 3.55 Billion TWD | 2.7% |
| 2016 Q1 | 3.62 Billion TWD | 4.99% |
| 2016 Q2 | 3.73 Billion TWD | 2.94% |
| 2015 Q4 | 3.45 Billion TWD | 4.95% |
| 2015 Q3 | 3.29 Billion TWD | -4.44% |
| 2015 Q2 | 3.44 Billion TWD | 4.79% |
| 2015 Q1 | 3.28 Billion TWD | 2.12% |
| 2015 FY | 3.45 Billion TWD | 7.33% |
| 2014 FY | 3.22 Billion TWD | 5.51% |
| 2014 Q4 | 3.22 Billion TWD | 1.65% |
| 2014 Q3 | 3.16 Billion TWD | -3.24% |
| 2014 Q2 | 3.27 Billion TWD | 4.98% |
| 2014 Q1 | 3.11 Billion TWD | 2.19% |
| 2013 FY | 3.05 Billion TWD | 92.83% |
| 2013 Q1 | 2.14 Billion TWD | 35.29% |
| 2013 Q2 | 2.22 Billion TWD | 3.71% |
| 2013 Q3 | 2.86 Billion TWD | 29.12% |
| 2013 Q4 | 3.05 Billion TWD | 6.44% |
| 2012 Q4 | 1.58 Billion TWD | 6.43% |
| 2012 Q2 | 1.49 Billion TWD | 1.35% |
| 2012 FY | 1.58 Billion TWD | 4.39% |
| 2012 Q1 | 1.47 Billion TWD | -2.81% |
| 2012 Q3 | 1.48 Billion TWD | -0.42% |
| 2011 Q1 | 1.47 Billion TWD | -2.19% |
| 2011 Q2 | 1.51 Billion TWD | 2.61% |
| 2011 Q3 | 1.53 Billion TWD | 1.64% |
| 2011 Q4 | 1.51 Billion TWD | -1.2% |
| 2011 FY | 1.51 Billion TWD | 0.79% |
| 2010 FY | 1.5 Billion TWD | 20.16% |
| 2010 Q4 | 1.5 Billion TWD | 0.0% |
| 2009 FY | 1.25 Billion TWD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Grape King Bio Ltd | 15.51 Billion TWD | 56.867% |
| Standard Chem & Pharm CO., LTD. | 11.18 Billion TWD | 40.201% |
| Maywufa Company Ltd. | 2.83 Billion TWD | -136.249% |
| ScinoPharm Taiwan, Ltd. | 11.72 Billion TWD | 42.919% |
| Lotus Pharmaceutical Co., Ltd. | 32.99 Billion TWD | 79.72% |
| LIWANLI Innovation Co., Ltd. | 834.17 Million TWD | -702.081% |
| YungShin Global Holding Corporation | 11.51 Billion TWD | 41.882% |
| PhytoHealth Corporation | 2.35 Billion TWD | -184.65% |
| Formosa Laboratories, Inc. | 13.63 Billion TWD | 50.934% |
| PharmaEssentia Corporation | 27.26 Billion TWD | 75.464% |
| Bora Pharmaceuticals Co., LTD. | 25.05 Billion TWD | 73.293% |